Fig 1: Elevated ADAM12 expression in radio-resistant OSCC cells. Expression profile of ADAM12 in patients with head and neck squamous cell carcinomas was searched in TCGA database (A). RT-qPCR (B) and Western blot (C) were applied to determine the expression level of ADAM12 in OSCC cell lines (HSC2, HSC4 and SCC4) and NHOK cells. The alternation on ADAM12 expression in HSC2 cell after radiation under 5 Gy, 10 Gy and 20 Gy was determined by RT-qPCR (D) and western blot (E). n=3, *p<0.05; **p<0.01. OSCC, oral squamous cell carcinoma.
Fig 2: ADAM12 increases the radio-resistance in OSCC cells. ADAM12 knockdown or overexpression was achieved in HSC2 cells. A,B) RT-qPCR (A) and Western blot (B) were used to verify the transfection efficiency of ADAM12. Cell viability, migration, proliferation and apoptosis were determined by CCK-8 (C), scratch assay (D), clone formation assay (E) and flow cytometry (F). n=3; *p<0.05 compared with control group; **p<0.01 compared with control group; #p<0.05 compared with IR group; ##p<0.01 compared with IR group; OSCC, oral squamous cell carcinoma.
Fig 3: ADAM12 increases the radio-resistance in OSCC cells. ADAM12 knockdown or overexpression was achieved in HSC2 cells. A,B) RT-qPCR (A) and Western blot (B) were used to verify the transfection efficiency of ADAM12. Cell viability, migration, proliferation and apoptosis were determined by CCK-8 (C), scratch assay (D), clone formation assay (E) and flow cytometry (F). n=3; *p<0.05 compared with control group; **p<0.01 compared with control group; #p<0.05 compared with IR group; ##p<0.01 compared with IR group; OSCC, oral squamous cell carcinoma.
Fig 4: miR-29a-3p by binding ADAM12 regulate the radio-sensitivity of OSCC cells. HSC2 cells were transfected or co-transfected with miR-29a-3p or ADAM12 related plasmids. Cell viability, migration, proliferation and apoptosis were determined by CCK-8 (A), scratch assay (B), clone formation assay (C) and flow cytometry (D). *p<0.05 compared with control group; **p<0.01 compared with control group; #p<0.05 compared with IR group; ##p<0.01 compared with IR group.
Fig 5: Distinct distribution of EZH2 and ADAM12 in human placental villi. A, B Immunofluorescent staining showed that EZH2 (red) was localized mainly in the cytotrophoblast (CTB) but not the syncytiotrophoblast (STB) which was stained for 11ß-HSD2 (green) at both early and term pregnancies. Nuclei were counterstained blue with DAPI. Immunohistochemical staining revealed a similar distribution pattern of EZH2. C, D Immunofluorescent staining showed that ADAM12 (green) was mainly localized in the syncytiotrophoblast (STB) and to a much lesser extent in the cytotrophoblast (CTB) at both early and term pregnancies. Nuclei were counterstained blue with DAPI. Immunohistochemical staining revealed a similar distribution pattern ADAM12. Non-immune serum served as negative control (NC). Scale bars, 20 µm
Supplier Page from Abcam for Anti-ADAM12 antibody